Author

Cristina Rodriguez

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Cristina Rodriguez  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Cristina Rodriguez  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

Cristina Rodriguez  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Cristina Rodriguez  et al.

MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU
MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU

Cristina Rodriguez  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

Cristina Rodriguez  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Cristina Rodriguez  et al.

LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY
LONG-TERM DURABILITY AND SAFETY OF USTEKINUMAB (UST) IN PATIENTS WITH ACTIVE CROHN'S DISEASE (CD) IN REAL LIFE: SUSTAIN STUDY

Cristina Rodriguez  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Cristina Rodriguez  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

Cristina Rodriguez  et al.

COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY
COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY

Cristina Rodriguez  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Cristina Rodriguez  et al.

Item 1 - 12 / 12
1